Nalu Bio key facts
- Developer of a drug discovery tool designed to accelerate the development of prescription and nonprescription health products targeting the endocannabinoid system (ECS).
- It has raised $13.5M across 2 recorded rounds; the latest was Accelerator/Incubator in Mar 2025.
- Notable investors include Springboard Enterprises, Flybridge (New York), XFactor Ventures, Sacramento Angels, Bonaventure Equity — 10 tracked in total.
- Nalu Bio has filed 1 Form D with the SEC, most recently Mar 2023 ($4.8M sold to 11 investors).
- Status: Privately Held (backing).
- ·Watch Nalu Bio: the Monday email on marks, rounds and moves
Nalu Bio funding rounds
2 roundsHow much has Nalu Bio raised?
Nalu Bio has raised $13.5 million in total; 2 of its rounds are on record. The largest on record was a $4.8 million seed round in Jan 2023; the most recent was an accelerator round in Mar 2025.
Nalu Bio has filed 1 Form D with the SEC, most recently in Mar 2023 ($4.8 million sold to 11 investors).
Nalu Bio investors
10 investors are on record for Nalu Bio, including Springboard Enterprises, Flybridge (New York), XFactor Ventures and Sacramento Angels. The seed round in Jan 2023 drew 11 investors.
About Nalu Bio
Developer of a drug discovery tool designed to accelerate the development of prescription and nonprescription health products targeting the endocannabinoid system (ECS). The company's platform combines generative artificial intelligence with emerging science to design, model, and screen novel compounds, enabling the health and wellness market to address critical issues such as pain, weight management, stress, and sleep disorders with minimal side effects on a global scale.
- Industry
- Other Pharmaceuticals and Biotechnology
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2019
- Employees
- 19
- Website
- nalubio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Nalu Bio doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.